Wendy Greenwood

Wendy Greenwood

Auto-generated profile, based on publicly available information

Wendy Greenwood

Department of Oncology, Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, United Kingdom

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 November 2014 in Nature
Verified
Journal Article
Closed access
PDF file
PEPeter Eirew
Peter Eirew
ASAdi Steif
Adi Steif
JKJaswinder Khattra
Jaswinder Khattra
GHGavin Ha
Gavin Ha
DYDamian Yap
Damian Yap
SASamuel Aparicio
Samuel Aparicio

1 September 2016 in Cell
Verified
Journal Article
Open access
ABAlejandra Bruna
Alejandra Bruna
OROscar M. Rueda
Oscar M. Rueda
WGWendy Greenwood
Wendy Greenwood
ABAnkita Sati Batra
Ankita Sati Batra
MCMaurizio Callari
Maurizio Callari
CCCarlos Caldas
Carlos Caldas
The inter- and intra-tumor heterogeneity of breast cancer needs to be adequately captured in pre-clinical models. We have created a large collection of breast cancer patient-derived tumor xenografts (PDTXs), in which the morphological and molecular characteristics of the originating tumor are preserved through passaging in the mouse. An integrated platform combining in vivo maintenance of these PDTXs along with short-term cultures of PDTX-derived tumor cells (PDTCs) was optimized. Remarkably, the intra-tumor genomic clonal architecture present in the originating breast cancers was mostly preserved upon serial passaging in xenografts and in short-term cultured PDTCs. We assessed drug responses in PDTCs on a high-throughput platform and validated several ex vivo responses in vivo. The biobank represents a powerful resource for pre-clinical breast cancer pharmacogenomic studies (http://caldaslab.cruk.cam.ac.uk/bcape), including identification of biomarkers of response or resistance.

1 November 2019 in Cell
Verified
Journal Article
Open access
ELEmma Laks
Emma Laks
AMAndrew McPherson
Andrew McPherson
HZHans Zahn
Hans Zahn
DLDaniel Lai
Daniel Lai
ASAdi Steif
Adi Steif
SSSohrab P. Shah
Sohrab P. Shah
Accurate measurement of clonal genotypes, mutational processes, and replication states from individual tumor-cell genomes will facilitate improved understanding of tumor evolution. We have developed DLP+, a scalable single-cell whole-genome sequencing platform implemented using commodity instruments, image-based object recognition, and open source computational methods. Using DLP+, we have generated a resource of 51,926 single-cell genomes and matched cell images from diverse cell types including cell lines, xenografts, and diagnostic samples with limited material. From this resource we have defined variation in mitotic mis-segregation rates across tissue types and genotypes. Analysis of matched genomic and image measurements revealed correlations between cellular morphology and genome ploidy states. Aggregation of cells sharing copy number profiles allowed for calculation of single-nucleotide resolution clonal genotypes and inference of clonal phylogenies and avoided the limitations of bulk deconvolution. Finally, joint analysis over the above features defined clone-specific chromosomal aneuploidy in polyclonal populations.

18 February 2011 in EMBO Molecular Medicine
Verified
Journal Article
Open access
PDF file
DHDaniel G. Holland
Daniel G. Holland
ABAngela Burleigh
Angela Burleigh
AGAnna Git
Anna Git
MGMae A. Goldgraben
Mae A. Goldgraben
PPPedro A. Perez‐Mancera
Pedro A. Perez‐Mancera
CCCarlos Caldas
Carlos Caldas
The telomeric amplicon at 8p12 is common in oestrogen receptor‐positive (ER+) breast cancers. Array‐CGH and expression analyses of 1172 primary breast tumours revealed that ZNF703 was the single gene within the minimal amplicon and was amplified predominantly in the Luminal B subtype. Amplification was shown to correlate with increased gene and protein expression and was associated with a distinct expression signature and poor clinical outcome. ZNF703 transformed NIH 3T3 fibroblasts, behaving as a classical oncogene, and regulated proliferation in human luminal breast cancer cell lines and immortalized human mammary epithelial cells. Manipulation of ZNF703 expression in the luminal MCF7 cell line modified the effects of TGFβ on proliferation. Overexpression of ZNF703 in normal human breast epithelial cells enhanced the frequency of in vitro colony‐forming cells from luminal progenitors. Taken together, these data strongly point to ZNF703 as a novel oncogene in Luminal B breast cancer.

1 January 2012 in Nature Communications
Verified
Journal Article
Open access
PDF file
ABAlejandra Bruna
Alejandra Bruna
WGWendy Greenwood
Wendy Greenwood
JQJohn Le Quesne
John Le Quesne
ATAndrew Teschendorff
Andrew Teschendorff
DMDiego Miranda-Saavedra
Diego Miranda-Saavedra
CCCarlos Caldas
Carlos Caldas
The role of transforming growth factor-beta (TGFβ) in the progression of different molecular subtypes of breast cancer has not been clarified. Here we show that TGFβ increases breast tumour-initiating cell (BTIC) numbers but only in claudinlow breast cancer cell lines by orchestrating a specific gene signature enriched in stem cell processes that predicts worse clinical outcome in breast cancer patients. NEDD9, a member of the Cas family of integrin scaffold proteins, is necessary to mediate these TGFβ-specific effects through a positive feedback loop that integrates TGFβ/Smad and Rho-actin-SRF-dependent signals. In normal human mammary epithelium, TGFβ induces progenitor activity only in the basal/stem cell compartment, where claudinlow cancers are presumed to arise. These data show opposing responses to TGFβ in both breast malignant cell subtypes and normal mammary epithelial cell subpopulations and suggest therapeutic strategies for a subset of human breast cancers.

5 January 2018 in BMC Genomics
Verified
Journal Article
Open access
PDF file
MCMaurizio Callari
Maurizio Callari
ABAnkita Sati Batra
Ankita Sati Batra
RBRajbir Nath Batra
Rajbir Nath Batra
SSStephen-John Sammut
Stephen-John Sammut
WGWendy Greenwood
Wendy Greenwood
CCCarlos Caldas
Carlos Caldas
Patient-Derived Tumour Xenografts (PDTXs) have emerged as the pre-clinical models that best represent clinical tumour diversity and intra-tumour heterogeneity. The molecular characterization of PDTXs using High-Throughput Sequencing (HTS) is essential; however, the presence of mouse stroma is challenging for HTS data analysis. Indeed, the high homology between the two genomes results in a proportion of mouse reads being mapped as human. In this study we generated Whole Exome Sequencing (WES), Reduced Representation Bisulfite Sequencing (RRBS) and RNA sequencing (RNA-seq) data from samples with known mixtures of mouse and human DNA or RNA and from a cohort of human breast cancers and their derived PDTXs. We show that using an In silico Combined human-mouse Reference Genome (ICRG) for alignment discriminates between human and mouse reads with up to 99.9% accuracy and decreases the number of false positive somatic mutations caused by misalignment by >99.9%. We also derived a model to estimate the human DNA content in independent PDTX samples. For RNA-seq and RRBS data analysis, the use of the ICRG allows dissecting computationally the transcriptome and methylome of human tumour cells and mouse stroma. In a direct comparison with previously reported approaches, our method showed similar or higher accuracy while requiring significantly less computing time. The computational pipeline we describe here is a valuable tool for the molecular analysis of PDTXs as well as any other mixture of DNA or RNA species.